<DOC>
	<DOCNO>NCT00329693</DOCNO>
	<brief_summary>Women include study undergo control ovarian hyperstimulation assist reproductive technology ( ART ) present sign moderate risk develop OHSS .</brief_summary>
	<brief_title>Study Assessing Effect 3-week Treatment With One Three Oral Doses Quinagolide</brief_title>
	<detailed_description>No data enter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Quinagolide</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed Informed Consent Form , prior screen evaluation 2 . In good physical mental health 3 . Premenopausal females age 2137 year ( inclusive ) time randomisation 4 . Infertility least 1 year randomisation , except proven bilateral tubal infertility Exclusion Criteria 1 . Any clinically significant systemic disease 2 . Endocrine metabolic abnormality ( pituitary , adrenal , pancreas , liver kidney ) 3 . History recurrent miscarriage 4 . Undiagnosed vaginal bleeding</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>